PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?

New Zealand Medical Journal

Volumn 119, Issue 1235, 2006, Pages

  Rosevear, Martin ^a  

^a Outcome Management Services   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; BUDGET; CARDIOTOXICITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG FATALITY; EARLY CANCER; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HOSPITAL COST; HOSPITAL SERVICE; HUMAN; NEW ZEALAND; QUALITY ADJUSTED LIFE YEAR; BREAST TUMOR; CANCER STAGING; DRUG APPROVAL; DRUG COST; ECONOMICS; FEMALE; GOVERNMENT; HEALTH CARE POLICY; PUBLIC HEALTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG APPROVAL; DRUG COSTS; FEMALE; GOVERNMENT AGENCIES; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; NATIONAL HEALTH PROGRAMS; NEOPLASM STAGING; NEW ZEALAND;

EID: 33745061040     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. Available online. URL: http://content.nejm.org/cgi/ content/full/353/16/1659 Accessed June 2006.
2. Hayman K. Warning over Herceptin hype. Christchurch: The Press; 2006. Available online. URL: http://www.stuff.co.nz/stuff/ 0,2106,3621782a7144,00.html Accessed June 2006.
3. Martin N. Woman wins fight for breast cancer drug. London: Daily Telegraph (UK); 2006. Available online http://www.telegraph.co.uk/news/ main.jhtml?xml=/news/2006/04/13/nhercep13.xml Accessed June 2006.
4. Metcalfe S, Dougherty S, Brougham M, Moodie P. PHARMAC measures savings elsewhere to the health sector. N Z Med J. 2003:116(1170). URL:. http://www.nzma.org.nz/journal/116-1170/362/
5. National Health Service. TA34 Breast cancer - trastuzumab: Guidance. London: National Institute for Clinical Excellence (NICE); 2002. Available online. URL: http://www.nice.org.uk/page.aspx?o=29280 Accessed June 2006.
6. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal of Clinical Oncology. 2004;22:854-63. Available online. URL: http://www.jco.org/cgi/content/full/22/5/854 Accessed June 2006.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005;353:1673-84. Available online. URL: http://content.nejm.org/cgi/ content/full/353/16/1673 Accessed June 2006.
8. PTAC meeting minutes for February 2006. Wellington: PHARMAC; 2006. Available online. URL: http://www.pharmac.govt.nz/pdf/ptacmins.pdf Accessed June 2006.
9. Survival results of Romond paper can be found at: http://content.nejm.org/cgi/content/full/353/16/1673
10. Statistics New Zealand. Total Female Population Life Table 2000-2002. Available online. URL: http://www.stats.govt.nz/NR/rdonlyres/ 8EA99547-7E92-4FDB-9BCB-4F2807914AC2/0/App1Tables.x1s [Click on Table A1.2 tab at the foot of the spreadsheet.] Accessed June 2006.
11. PHARMAC Annual Plan 2004/2005. Wellington: PHARMAC; 2004. Available online. URL: http://www.pharmac.govt.nz/pdf/AP2005.pdf Accessed June 2006.
12. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol. 2006;17:381-90.
13. Media release. Herceptin (trastuzumab) provisionally approved. Wellington: Ministry of Health; 2006. Available online. URL: http://www.moh.govt.nz/moh.nsf/by+unid/ 6C8344DC08AE29C9CC257139007FA389?Open Accessed June 2006.
14. Media release. Cancer drug funding a challenge - PHARMAC. Wellington: PHARMAC. Available online. URL: http://www.pharmac.govt.nz/pdf/ 071205a.pdf Accessed June 2006.